Abuse and misuse of second-generation antipsychotics: An analysis using VigiBase, the World Health Organisation pharmacovigilance database.
abuse
disproportionality analysis
misuse
second-generation antipsychotics
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
16
05
2022
received:
18
01
2022
accepted:
18
05
2022
pubmed:
29
5
2022
medline:
14
9
2022
entrez:
28
5
2022
Statut:
ppublish
Résumé
The study aim was to assess the abuse/misuse potential of second-generation antipsychotics (SGAPs) using VigiBase data. We extracted individual case safety reports of "Drug abuse, dependence and withdrawal" involving SGAPs up to June 2018. We assessed disproportionate reporting by calculating the information component, considering the lower end of the 95% credibility interval for the information component (IC
Substances chimiques
Antipsychotic Agents
0
Benzodiazepines
12794-10-4
Quetiapine Fumarate
2S3PL1B6UJ
Olanzapine
N7U69T4SZR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4646-4653Informations de copyright
© 2022 British Pharmacological Society.
Références
Montastruc F, Benard-Laribiere A, Noize P, et al. Antipsychotics use: 2006-2013 trends in prevalence and incidence and characterization of users. Eur J Clin Pharmacol. 2018;74(5):619-626. doi:10.1007/s00228-017-2406-0
Rowe DL. Off-label prescription of quetiapine in psychiatric disorders. Expert Rev Neurother. 2007;7(7):841-852. doi:10.1586/14737175.7.7.841
Schifano F, Chiappini S, Corkery JM, Guirguis A. Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. Brain Sci. 2018;8(4):73. doi:10.3390/brainsci8040073
Sansone RA, Sansone LA. Is seroquel developing an illicit reputation for misuse/abuse? Psychiatry. 2010;7(6):13-16.
Chiappini S, Schifano F. What about “Pharming”? Issues Regarding the Misuse of Prescription and Over-the-Counter Drugs. Brain Sci. 2020;10(10):736. doi:10.3390/brainsci10100736
Mattson ME, Albright VA, Yoon J, Council CL. Emergency Department Visits Involving Misuse and Abuse of the Antipsychotic Quetiapine: Results from the Drug Abuse Warning Network (DAWN). Subst Abuse Res Treat. 2015;9:39-46. doi:10.4137/SART.S22233
Cepaityte D, Siafis S, Papazisis G. Safety of antipsychotic drugs: A systematic review of disproportionality analysis studies. Behav Brain Res. 2021;404:113168. doi:10.1016/j.bbr.2021.113168
Chiappini S, Schifano F. Is There a Potential of Misuse for Quetiapine? Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database. J Clin Psychopharmacol. 2018;238(1):72-79. doi:10.1097/JCP.0000000000000814
Evoy KE, Teng C, Encarnacion VG, et al. Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics. Subst Abuse Res Treat. 2019;13:1-8. doi:10.1177/1178221819844205
VigiBase. Uppsala Monitoring Centre [Internet]. Available from: https://who-umc.org/vigibase/
Nguyen TT, Pariente A, Montastruc JL, et al. An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders. Br J Clin Pharmacol. 2017;83(3):612-622. doi:10.1111/bcp.13145
Gouverneur A, Ferreira A, Morival C, Pageot C, Tournier M, Pariente A. A safety signal of somnambulism with the use of antipsychotics and lithium: A pharmacovigilance disproportionality analysis. Br J Clin Pharmacol. 2021;87(10):3971-3977. doi:10.1111/bcp.14818
Carnovale C, Mahzar F, Scibelli S, et al. Central nervous system-active drug abused and overdose in children: a worldwide exploratory study using the WHO pharmacovigilance database. Eur J Pediatr. 2019;178(2):161-172. doi:10.1007/s00431-018-3281-0
Medical Dictionary for Adverse Drug Reactions. MedDRAVersion 21.0 English. 2018. Available at: https://admin.meddra.org/sites/default/files/guidance/file/smq_intguide_21_0_english.pdf. Accessed April 25, 2022.
WHO Expert Committee on Addiction-Producing Drugs. Thirteenth report of the WHO Expert Committee. 2016. Available at: https://apps.who.int/iris/handle/10665/40580. Accessed April 07, 2022.
Alexander SP, Christopoulos A, Davenport AP, et al. The Concise Guide to PHARMACOLOGY 2017/2018: G protein-coupled receptors. Br J Pharmacol. 2017;174(S1):S1-S446. doi:10.1111/bph.13882
Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905-908. doi:10.1111/j.1365-2125.2011.04037.x
Robert C, Saavedra L, Gaynes BN, et al. Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Feb. https://effectivehealthcare.ahrq.gov/
Peyriere H, Diot C, Eiden C, Petit P, Réseau des Centres d'Addictovigilance. Abuse liability of quetiapine (Xeroquel®). Therapie. 2016; Online ahead of print. doi:10.2515/therapie/2015048
Vento AE, Kotzalidis GD, Cacciotti M, et al. Quetiapine Abuse Fourteen Years Later: Where Are We Now? Syst Rev Subst Use Misuse. 2020;55(2):304-313. doi:10.1080/10826084.2019.1668013
McKean A, Monasterio E. Off-label use of atypical antipsychotics. Cause for concern? CNS Drugs. 2012;26(5):383-390. doi:10.2165/11632030-000000000-00000
Reccoppa L. Less abuse potential with XR formulation of quetiapine? Am J Addict. 2010;20:178. doi:10.1111/j.1521-0391.2010.00104.x
James PD, Fida AS, Konovalov P, Smyth BP. Non-medical use of olanzapine by people on methadone treatment. BJ Psych Bull. 2016;40(6):314-317. doi:10.1192/pb.bp.115.052886
Reeves RR. Abuse of olanzapine by substance abusers. J Psychoactive Drugs. 2007;39(3):297-299. doi:10.1080/02791072.2007.10400617
Valeriani G, Corazza O, Bersani FS, et al. Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms. Hum Psychopharmacol. 2015;30(4):249-254. doi:10.1002/hup.2431
Murphy D, Bailey K, Stone M, Wirshing WC. Addictive potential of quetiapine. Am J Psychiatry. 2008;165(7):918. doi:10.1176/appi.ajp.2008.08020277
Harris MG, Bharat C, Glantz MD, et al. Cross-national patterns of substance use disorder treatment and associations with mental disorder comorbidity in the WHO World Mental Health Surveys. Addiction. 2019;114:1446-1459.
Aringhieri S, Carli M, Kolachalam S, et al. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacol Therap. 2018;192:20-41. doi:10.1016/j.pharmthera.2018.06.012
Lopez-Munoz F, Alamo C. Active metabolite as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Front Psych. 2013;4:1-8.
Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity. Neuropsychopharmacology. 2008;33(10):2303-2312. doi:10.1038/sj.npp.1301646
Althobaiti YS. Quetiapine-induced place preference in mice: possible dopaminergic pathway. Pharmaceticals. 2021;14(2):156. doi:10.3390/ph14020156
Chien-Han L. Olanzapine abuse was relieved after switching to aripiprazole in a patient with psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1363-1364. doi:10.1016/j.pnpbp.2010.07.031
Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(Suppl(19)):6-12.
Forrester MB. Pattern of ziprasidone exposures reported to Texas poison centers, 2001-2005. Hum Exp Toxicol. 2008;27(4):355-361. doi:10.1177/0960327108091170